Abstract
Editorials7 July 2009Angiotensin-Receptor Blockers in the Prevention or Treatment of MicroalbuminuriaPatrick S. Parfrey, MDPatrick S. Parfrey, MDFrom Health Sciences Centre, Memorial University, St. John's, Newfoundland A1B 3V6, Canada.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-151-1-200907070-00011 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Type 1 and type 2 diabetes mellitus are the most frequent causes of end-stage renal disease in the United States (1). The natural history of diabetic nephropathy starts with microalbuminuria, which may progress to macroalbuminuria, gradual deterioration in glomerular filtration rate (GFR), and eventually end-stage kidney disease. Microalbuminuria in diabetes strongly predicts end-stage renal disease and adverse cardiovascular events (2–4). Although inhibitors of the renin–angiotensin system (RAS) have become the mainstays of treating established diabetic nephropathy (5), the role of these agents in the early phases of diabetic nephropathy is unclear. Kidney damage may occur in diabetics who do not ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
